Abstract
Estrogen receptor α (ERα)-positive breast cancers often find a way to circumvent endocrine therapies such as tamoxifen. A newly described ERα kinase, lemur tyrosine kinase-3 (LMTK3), may provide both a diagnostic advance and a new therapeutic target to fight these resistant, aggressive tumors.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
